Tromsø, Norway, 9th December 2022 – ArcticZymes Technologies ASA (OSE: AZT) upscales the production of ArcticZymes Proteinase and launches ArcticZymes Proteinase Glycerol FREE
ArcticZymes Technologies (AZT) has successfully upscaled the production of ArcticZymes Proteinase. This will allow the Company to meet growing demand from new and existing customers, thereby strengthening the Company´s position as a supplier of critical components in molecular diagnostics and biomanufacturing applications.
Additionally, AZT has launched a glycerol-free formulation of the proteinase. This was facilitated by the upscaling of the proteinase enzyme. This glycerol-free formulation will enable the Company to support customers requiring a lyophilization compatible formulation of the proteinase for use in high throughput molecular diagnostic workflows.
Together the upscaled production capacity and addition of a glycerol-free formulation, greatly increases the market reach for ArcticZymes Proteinase products, both being instrumental factors for sales growth while ensuring a reliable and relevant product offering to existing and new customers.
ArcticZymes Technologies ASA, CEO, Jethro Holter said:
“The novel features of ArcticZymes Proteinase have already enabled customers to circumvent technical barriers that other enzymes such as Proteinase K cannot overcome in molecular diagnostics workflows. In biomanufacturing there is a growing interest in ArcticZymes Proteinase for potential use in gene therapy related applications.”
For more information, please contact:
CEO, Jethro Holter T: +47 46 85 91 46
CFO, Børge Sørvoll T: +47 95 29 01 87 / E: firstname.lastname@example.org